Synergy Pharmaceuticals
SGYP
SGYP was delisted on the 7th of March, 2019.
77 hedge funds and large institutions have $116M invested in Synergy Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 18 reducing their positions, and 6 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 18
84% more call options, than puts
Call options by funds: $381K | Put options by funds: $207K
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
39% more capital inflows, than outflows
Capital inflows: $14.3M | Capital outflows: $10.3M
7% more funds holding
Funds holding: 72 → 77 (+5)
0.89% more ownership
Funds ownership: 27.22% → 28.1% (+0.89%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$2.84M |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
+$1.87M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.32M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$1.27M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridger Management
New York
|
-$4.6M |
| 2 |
Driehaus Capital Management
Chicago,
Illinois
|
-$1.05M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$885K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$543K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$492K |
SGYP Hedge Fund Activity: Q3 2013 in Review
77 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals (SGYP) for Q3 2013, worth a combined $116M — up 9.2% from $106M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SGYP positions and 6 closed out — a net gain of 5 holders — while 35 added to existing stakes and 18 trimmed.
The largest buyer was UBS AM, opening a new position worth an estimated $2.84M. The largest seller was Bridger Management, exiting entirely with an estimated $4.6M sold.
- 77 institutional investors held Synergy Pharmaceuticals (SGYP) as of Q3 2013, up from 72 in Q2 2013.
- Funds reported $116M of Synergy Pharmaceuticals stock for Q3 2013, up 9.2% quarter-over-quarter.
- 11 funds opened new Synergy Pharmaceuticals positions in Q3 2013 and 6 closed out, a net change of +5 holders.
- The largest Synergy Pharmaceuticals buyer in Q3 2013 was UBS AM, an estimated $2.84M added.
- The largest Synergy Pharmaceuticals seller in Q3 2013 was Bridger Management, an estimated $4.6M sold.
Based on aggregated 13F filings for Q3 2013.